Efalizumab

CLINICAL USE

Treatment of patients with moderate to severe chronic plaque psoriasis, who have failed to respond to other therapies or who are unable to take other therapies

DOSE IN NORMAL RENAL FUNCTION

Initially: 0.7 mg/kg followed by weekly injections of 1 mg/kg (maximum single dose should be <200 mg) for 12 weeks

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :150 000

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data

%Excreted unchanged in urine &nbsp &nbsp : No data

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.058–0.11

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :13–35 days

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Use with caution

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL/min

HDF/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR=10–20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsImmunosuppressants: may potentiate the effect of immunosuppressantsVaccines: do not administer live vaccines during treatment

ADMINISTRATION

Reconstition

With solvent provided (water for injection)

Route

SC

Rate of Administration

–

Comments

–

OTHER INFORMATION

Use with caution in patients with a history of recurrent infections

Contraindicated in people who are immunosuppressed

Tags: post-by-auto-php